We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 43 of 311 for:    hepatitis b | Recruiting, Not yet recruiting, Available Studies

Epidemiology of Hepatitis B, C and Delta in Reunion Island (HEPEPID)

This study is not yet open for participant recruitment.
Verified November 2017 by Centre Hospitalier Universitaire de la Réunion
Sponsor:
ClinicalTrials.gov Identifier:
NCT03362866
First Posted: December 5, 2017
Last Update Posted: December 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de la Réunion
  Purpose
Viral hepatitis B, C and Δ represent a global public health problem for which France was very early mobilized. Despite this, in its foreword, the Dhumeaux report on "Management of people infected with hepatitis B or hepatitis C viruses" identifies a residual area of weakness in this care that is the incomplete regional epidemiological data in the Overseas Territories. The specific ethno-socio-cultural characteristics of these territories make it difficult to transpose data from the mainland France. This study aims at improving our knowledge on the characteristics of patients with hepatitis B, C and Δ in Reunion Island, their follow-up, their evolution and complications.

Condition
Hepatitis B Hepatitis C Hepatitis D

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Epidemiology of Hepatitis B, C and Delta in Reunion Island

Resource links provided by NLM:


Further study details as provided by Centre Hospitalier Universitaire de la Réunion:

Primary Outcome Measures:
  • Number of patients with hepatitis B, C and Δ in Reunion [ Time Frame: Up to 5 years ]
    Hepatitis diagnosis will be made according to the ongoing guidelines in France (referred by the National AIDS and Hepatitis Research Agency (ANRS)


Estimated Enrollment: 2000
Anticipated Study Start Date: April 2018
Estimated Study Completion Date: April 2023
Estimated Primary Completion Date: April 2023 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Hepatitis B, C, D patients in Reunion Island
Criteria

Inclusion Criteria:

Major patient

  • with confirmed HBsAg and / or anti HCV positive Ab
  • residing in Reunion Island
  • followed in one of the participating centers

Exclusion Criteria:

• Patient carrying isolated anti HBc antibodies

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03362866


Contacts
Contact: Olivier Maillard, PharmD +262693025589 olmaillard@yahoo.fr

Sponsors and Collaborators
Centre Hospitalier Universitaire de la Réunion
  More Information

Responsible Party: Centre Hospitalier Universitaire de la Réunion
ClinicalTrials.gov Identifier: NCT03362866     History of Changes
Other Study ID Numbers: 2016/CHU/14
First Submitted: November 24, 2017
First Posted: December 5, 2017
Last Update Posted: December 5, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis B
Hepatitis D
Hepatitis, Viral, Human
Liver Diseases
Digestive System Diseases
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Hepadnaviridae Infections
DNA Virus Infections